Latest Regulatory Engagement News

Norfolk Metals has completed Phase #1 drilling at its Carmen Copper Project in Chile, validating higher-grade copper mineralisation and historical resource estimates. The company remains suspended from ASX pending a material acquisition and regulatory approvals, while bolstering its balance sheet with a $2.1 million capital raise.

Admiralty Resources saw a quarter-on-quarter drop in iron ore output at its Mariposa project but advanced key infrastructure and appointed a new auditor to support its production phase.

Clime Investment Management has accelerated its strategic pivot by selling its retail advice operations and agreeing to divest its Separately Managed Accounts business, while reporting improved investment performance and a strengthened balance sheet.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

TrivarX appoints Dr Danielle Meyrick as CEO to spearhead clinical trials and commercialisation of its novel stable isotope MRI brain cancer imaging platform, with Phase 1 studies on track for completion this year.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Ardiden Limited has secured the historic Golden Patricia Gold Mine from Barrick, consolidating a high-grade gold corridor in Ontario’s Pickle Lake district and opening significant exploration opportunities.

Alterity Therapeutics has secured FDA alignment on the chemistry and manufacturing controls for its ATH434 Phase 3 trial in Multiple System Atrophy, marking a pivotal regulatory milestone ahead of the planned mid-2026 End-of-Phase 2 meeting.